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Introduction
Th  e question of whether randomized adjuvant trials in 
oncology are a necessity or a time-consuming luxury 
addresses one of the most complex aspects of human 
research and its clinical applications within public health. 
Randomized trials are an absolute necessity; they have 
resulted in hundreds of thousands of lives worldwide 
being saved in the decades since their inception. 
However, the present system of clinical trials based on an 
infrastructure devised over 40 years ago cannot now 
easily handle the rising challenges related to so many new 
developments occurring simultaneously. Human genome 
information, molecular classiﬁ   cation and techniques 
enabling the design of new agents based on tumor genetic 
characteristics will potentially result in the explosive 
development of new agents or diagnostic classiﬁ  ers that 
would accelerate the decline in mortality, especially from 
breast cancer. At present, however, all these require 
testing within the existing clinical trial infrastructure. 
Under the present system, excessive delays are inevitable, 
unless reforms are implemented that will dramatically 
accelerate the present process of ‘bench to clinic’.
A series of proposals was recently articulated regarding 
qualitatively new approaches towards clinical trials in 
breast cancer. Th  eir outline constitutes part of this 
invited review.
The clinical trial process
Current estimates of the interval between the ﬁ  rst 
evidence of eﬀ  ect of a new agent in stage IV disease and 
its introduction into guidelines in early breast cancer 
range from 15 to 20 years. Could this prohibitive delay be 
reduced to 5 years or less? Th  at is the question we are 
asking. In order to substantially reduce the testing period, 
a system of reforms within the clinical trial process must 
take place, ideally involving the entire international 
community.
While tighter international collaboration is a funda-
mental prerequisite for implementing these suggestions, 
indivi  dual aspects of the required reforms need to be 
articu  lated clearly, with two re-assuring conditions 
essential they must not jeopardize: the quality of drug 
research leading to level I evidence of beneﬁ  t or harm 
and the determination of safety.
Only limited aspects of the required reforms will be 
discussed here, with the main objective to initiate a 
dialogue among scientists to identify the mounting 
problems as a pre-requisite to the actual reform process 
on a larger scale.
Trials in stage IV breast cancer versus the adjuvant setting
Is stage IV breast cancer a good environment in which to 
test a new agent in complex random breast cancer trials? 
Th   is is our ﬁ  rst question, and its discussion may lead to 
modiﬁ   cations of the trial process leading to earlier 
implementation of neoadjuvant and adjuvant clinical trial 
testing.
Recent clinical evidence [1] has highlighted pivotal 
preclinical studies in bacteria and human cancer [2,3], 
conﬁ   rming that advanced disease is more resistant to 
antibiotics or oncology therapeutics than early disease. 
Th   is is probably due to the substantially higher absolute 
number and proportion of resistant mutants in late 
disease. Not surprisingly, it is expected that agents 
scoring some clinical beneﬁ  t in stage IV breast cancer 
typically would score a much higher beneﬁ   t in the 
adjuvant setting where there are many fewer residual 
cancer cells.
A review of outcomes of breast cancer therapies [1] 
evaluated all therapeutic regimens known to be eﬀ  ective 
in randomized trials in stage IV breast cancer, and then 
tested in an identical manner trials in the adjuvant setting 
of breast cancer - the ‘doubly tested trials’ (Table 1). Th  e 
review did not include incompletely tested agents or 
regimens, such as bevazcizumab (representing the class 
of angiogenesis inhibitors), due to either inconsistent 
eﬀ  ects in stage IV or absence of data from adjuvant trials, 
or both. Also, results of this review apply strictly to breast 
cancer, as diﬀ  erent solid tumors, such as colon cancer, 
may not allow this level of correlation. © 2010 BioMed Central Ltd
Randomized adjuvant trials in oncology: 




Faculty of Medicine and School of Population and Public Health, University of 
British Columbia, Vancouver, BC, V5Z 2N6, Canada
Ragaz Breast Cancer Research 2010, 12(Suppl 4):S14
http://breast-cancer-research.com/supplements/12/S4/S14
© 2010 BioMed Central LtdAnalyses of all the doubly tested trials have shown that 
if a signiﬁ  cant eﬀ  ect was shown in stage IV, even more 
beneﬁ   t was seen in the adjuvant setting (Table 1). 
Speciﬁ   cally, even though a superior response or even 
prolongation of survival in stage IV is seen with an agent, 
this seldom if ever results in a cure. In contrast, the same 
agents tested in the adjuvant setting improve both long-
term disease-free survival (DFS) and overall survival (OS) 
and thus impact cure rates signiﬁ  cantly (Table 1).
As a corollary, meta-analyses by the Oxford Overview 
Early Breast Cancer Trialists’ Collaborative Group [4,5] 
conﬁ  rmed a long-lasting 25 to 30% reduction in mortality 
from human breast cancer as a result of combination 
adjuvant chemotherapy, or tamoxifen or radiation. Yet 
none of these regimens or interventions produced long-
term survival in advanced disease.
Th   e legitimate question arises: could the early 
superiority of new agents identiﬁ  ed in the stage IV setting 
signal a future potential curative eﬀ  ect if used in the 
adjuvant setting? Could this information lead to a 
substantially faster next level of clinical trials in early 
disease than is presently the case? Probably yes, providing 
a set of reforms is implemented. If so, what would be the 
logistics of these reforms?
Th   e crux of our proposals involves a speedier start of 
coordinated neoadjuvant and adjuvant randomized 
controlled trials as soon as new agents have been shown 
to be eﬀ   ective in stage IV disease, with these trials 
starting simultaneously in multiple centers (Table 2). Th  e 
prospect of saving thousands of lives by the discovery of 
an eﬀ  ective agent in the stage IV setting should galvanize 
the oncology community towards rapidly testing the 
same treatment in early stages of disease. Th  us,  evidence 
of superiority from the stage IV setting should be the 
‘tipping point’ for launching a chain of multiple rapid 
trials in early disease, in the same way that any societal 
emergency should be handled when thousands of lives 
are at stake.
Th  e new strategy would propose starting with neo-
adjuvant trials after beneﬁ  t in stage IV is seen. If results 
from the neoadjuvant trials conﬁ  rm the superiority seen 
in stage IV disease, multi  center postoperative adjuvant 
trials would immediately follow. Th  e advantage of this 
sequence is that neoadjuvant trials could generate results 
based on pathology responses much faster than any other 
approach and could provide critically needed guidance 
for the design of adjuvant trials.
The neoadjuvant setting: the ideal model for early 
randomized design
Neoadjuvant (preoperative) chemotherapy trials have 
changed our way of thinking about cancer treatment in a 
number of ways [6-9]. While they conﬁ  rmed identical 
DFS and OS rates compared to the postoperative adju-
vant series, and have led to improved breast conser-
vation, the real novelty of the neoadjuvant approach is 
the provision of a setting that allows more precise and 
detailed assessment of the in vivo response to new thera-
peutics [6,10,11].
Th  e neoadjuvant setting permits repeated tissue test-
ing, with the potential to select individualized approaches 
according to evolving pathology or molecular response 
criteria [12]. Furthermore, assessment of the clinical, 
pathological and molecular biological responses [13,14] 
can conﬁ  rm the superiority or inferiority of new agents 
much faster and more reliably than prolonged random-
ized controlled trials presently conducted in stage IV 
[15]. Since neoadjuvant studies show a very good 
correlation between pathologic complete response (pCR) 
and outcome, achieving a higher pCR with a new agent - 
particularly if associated with a superior response in 
stage IV - would further conﬁ  rm superiority.
Th   e best example of this proof of principle is seen with 
the re-analysis of the National Surgical Adjuvant Breast 
and Bowel Project Protocol B-27 (NSABP B-27) trial: at 
the 68-month update, the addition of preoperative 
docetaxel to adriamycin and cyclophosphamide doubled 
the pCR rate from 13% to 26%, and improved the relapse-
free survival, despite the fact that no changes in OS were 
seen in this particular trial [13].
Table 1. Overview of breast cancer trials - the ‘doubly tested trials’
  Stage IV response rates  Adjuvant setting DFS hazards
Tamoxifen  30 to 40%  0.60 to 0.70
Cyclophosphamide (vincristine prednisolone)  40 to 80%  0.70
Anthracyclines versus cyclophosphamide  20 to 30%  0.80
Taxanes versus anthracyclines  20 to 30%  0.81
Aromatase inhibitors (letrozole) versus tamoxifen  30 to 40%  0.57
Trastuzumab versus placebo  40 to 50%  0.42 to 0.54
Curability  0%  15 to 40%
The same agents and regimens were tested in identical design and dose regimens, fi  rst in stage IV and then in the adjuvant setting. Comparison of fi  nal outcomes is 
shown, with eff  ect in stage IV expressed as response rates and eff  ect in the adjuvant setting expressed as disease free survival (DFS) rates, with appropriate hazard 
ratios; curability is also indicated.
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signaled a superiority of taxanes over anthracylines alone, 
a concept subsequently proved in the 2007 meta-analyses 
of all taxanes versus non-taxane regimens [13]. Th  ese 
trials showed signiﬁ  cantly superior DFS and OS when 
adding taxanes over regimens with anthracylines alone.
Additional studies subsequently indicated that the 
superiority of taxanes is restricted to certain cohorts, 
such as those with negative Her2 status [16] or those with 
negative estrogen receptors [16], but overall, taking into 
account all patients, the improved pCR rates with taxanes 
in the B-27 neoadjuvant trial antedated by many years 
the full meta-analysis documenting superiority of taxanes 
over anthracyclines alone in the adjuvant setting.
Other neoadjuvant studies have validated the use of 
molecular responses in the context of neaodjuvant trials, 
with the regimen-speciﬁ   c genomic signatures signiﬁ  -
cantly predicting pCR in patients treated with the 
appropriate regimens [12-17].
Th   ese observations constitute one of the most 
important aspects of our proposed new approach: testing 
in the neoadjuvant setting as a ﬁ  rst step oﬀ  ers the ability 
to more rapidly assess the tested agents - results become 
available within months rather than years. Secondly, 
rapid generation of these data would lead to a new 
dimension of information on new agents, with the rapidly 
growing ﬁ   elds of genomics, proteomics and tumor 
signatures also oﬀ  ering a potential for substantially faster 
development of individualized therapies and or 
development of new agents.
Th   us, the information gained from neoadjuvant testing 
is invaluable, and for the purpose of this review it 
represents excellent in vivo conﬁ  rmation of eﬀ  ects of new 
agents allowing a more rapid start of large adjuvant trials. 
Th   is concept, while articulated already in the 1980s [6], is 
rapidly gaining popularity, yet is presently underutilized 
with regard to new trial reforms, which we propose.
As a result of these considerations, the following changes 
to the current randomized controlled trial process are 
proposed.
Step 1: advanced disease
Initiate and complete phase I to III trials in advanced 
stage populations within a shorter time frame to deter-
mine safety and levels of eﬃ     cacy much more expe-
ditiously through a tighter coordination among multiple 
centers testing promising agents simultaneously in 
multiple randomized trials.
Step 2: the neoadjuvant setting
Once safety and eﬀ  ectiveness have been documented in 
stage IV disease, treatment modalities should be moved 
rapidly into randomized and non-randomized neoadju-
vant trials to conﬁ   rm clinical eﬀ   ectiveness and to 
elucidate pathologic and molecular responses.
Step 3: adjuvant setting
At the ﬁ   rst indication of clinical response and or 
advantage over conventional therapy seen in the 
neoadjuvant setting, large, internationally coordinated, 
randomized trials including 15,000 to 20,000 patients per 
trial should be initiated. Th   ese trials would be designed 
to also identify dose-response relationships, optimum 
duration of therapy and long-term safety.
Conclusion
Th  e science of human randomized clinical trials has 
undergone a major renaissance since the introduction of 
empiricism in the early 1900s. Th  e  eﬃ   ciency and speed 
with which the NSABP clinical trial group has generated 
important and reliable results has been truly remarkable. 
Starting in the 1970s, tests of new concepts, agents, and 
regimens have been completed virtually annually and 
accepted into guidelines shortly thereafter.
A similar renaissance is due in 2011. As the tempo of 
new agent discovery accelerates, it is becoming 
increasingly clear that the current clinical trial process 
and its regulatory processes are unable to keep up. A 
clinical trial process is described that could facilitate 
more eﬃ   cient progress, with the potential for beneﬁ  ting 
many more patients much sooner.
Table 2. Accelerating the transition from ‘bench’ to ‘clinic’ - proposed accelerated breast cancer clinical trial process
Year 1: stage IV testing (total 1 year)  i. Phase I to II testing, followed by RCT in stage IV. If eff  ect and safety seen, start neoadjuvant testing immediately
 
Years 2 to 3: neoadjuvant testing (2 years)  ii. Neaodjuvant setting for eff  ectiveness: if clinical, pathology and molecular responses of a novel agent and 
  regimen are confi  rmed follow with:
  iii. Randomized trials of the agents against the conventional approach, with repeated needle biopsies to 
  correlate clinical with pathologic and molecular responses
 
Years 3 to 5: adjuvant testing (total 2 years)  i. Large multicenter adjuvant trials with multiple international sites, involving more than 25,000 patients, to start 
  as soon as fi  rm responses are seen in the neoadjuvant setting
  ii. Objectives: dose response, therapy duration, long-term toxicity, and so on
RCT, randomized controlled trial.
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Unquestionably, progress in cancer management is 
happening in quantum leaps. Yet for many patients and 
their families, this progress is slow. We are extremely 
fortunate to have witnessed a steep decline in breast 
cancer mortality in the past decade, no doubt as a result 
of these innovations. However, this review shows that we 
could do much better.
Recommendations
As ﬁ  nal recommendations, we hope for an international 
consensus, that: the clinical trial process must be, and 
can be, accelerated; stage IV breast cancer is no longer 
the best setting to test new agents; we can do more and 
sooner if the principle arena of testing is shifted to the 
neoadjuvant and adjuvant settings; the transfer of 
positive results into community guidelines has to be 
expedited, with input by patient advocacy groups a 
strong consideration; the failure to apply mature results 
expeditiously should be considered a societal crisis.
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